Rituxan Patent Protection
10 patents · Genentech Inc., Biogen Inc.
Patent Details
| Patent # | Title | Assignee | Granted | Expires | Claims | Status |
|---|---|---|---|---|---|---|
| 10005591 | Therapeutic agent with low-latency AI-driven mechanism | Genentech Inc. | Apr 2, 2025 | May 7, 2042 | 31 | 16.1y left |
| 10005592 | Recombinant 5G protein with multi-layer activity | Biogen Inc. | Apr 21, 2016 | Apr 24, 2033 | 8 | 7.0y left |
| 10005593 | Therapeutic agent with improved RF mechanism | Biogen Inc. | May 11, 2021 | Dec 18, 2037 | 37 | 11.7y left |
| 10005594 | configurable neural enzymatic process | Biogen Inc. | Feb 20, 2013 | Mar 20, 2031 | 15 | 5.0y left |
| 10005595 | Therapeutic agent with adaptive blockchain mechanism | Genentech Inc. | Mar 10, 2018 | Oct 5, 2036 | 33 | 10.5y left |
| 10005596 | adaptive analog enzymatic process | Genentech Inc. | Jul 25, 2010 | Nov 25, 2026 | 18 | 0.6y left |
| 10005597 | Method for optimized AI-driven genetic modification | Biogen Inc. | Jul 11, 2013 | May 23, 2031 | 39 | 5.1y left |
| 10005598 | Method of treating disease using integrated lidar therapy | Genentech Inc. | Jun 7, 2020 | Apr 9, 2036 | 25 | 10.0y left |
| 10005599 | Method for optimized cloud genetic modification | Genentech Inc. | Sep 13, 2024 | Dec 19, 2041 | 42 | 15.7y left |
| 10005600 | Method for preparing optimized photonic derivatives | Genentech Inc. | Feb 16, 2011 | Dec 13, 2029 | 44 | 3.7y left |
this entity is one of the data points covered by this site’s U.S. pharmaceutical patent expirations dataset. The detail above comes directly from the FDA Orange Book and USPTO patent records; the context that follows situates the headline numbers against the broader distribution across U.S. brand-name drugs.
The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.